我國新冠病毒滅活疫苗獲批進入臨牀試驗大綱

The two vaccines are China's first batch of COVID-19 inactivated vaccines that have obtained clinical trial approval. Using killed pathogenic microorganisms for enhancing the immunogenicity, the vaccines have advantages of mature production process, controllable quality standards and wide protection range.

此次獲批進入臨牀試驗的兩款滅活疫苗是我國首批獲得臨牀研究批件的新冠病毒滅活疫苗，是一種殺死病原微生物但仍保持其免疫原性的疫苗，具有生產工藝成熟、質量標準可控、保護範圍廣等優點。

padding-bottom: 66.44%;">

They can be used for large-scale vaccination, and their safety and effectiveness can by judged by internationally accepted standards.

這兩款疫苗可用於大規模接種，並且有國際通行標準來判斷疫苗的安全性和有效性。

China has laid a solid foundation for research in inactivated vaccines, which has been widely used to fight hepatitis A, influenza, hand-foot-and-mouth disease and poliomyelitis.

我國的滅活疫苗有較好研究基礎，甲肝滅活疫苗、流感滅活（裂解）疫苗、手足口病滅活疫苗、脊髓灰質炎滅活疫苗等均已廣泛應用。